Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.

Cell Line, Tumor Deferasirox / pharmacology Humans Iron / metabolism Iron Chelating Agents / pharmacology Leukemia, Myeloid, Acute / metabolism Mitochondria / drug effects Protein Stability Proto-Oncogene Proteins c-mdm2 / metabolism Signal Transduction Tumor Suppressor Protein p53 / metabolism
Deferasirox MDM2 chelation iron leukemia mitochondria p21 p53 p73

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Oct 2020
Historique:
received: 27 08 2020
revised: 02 10 2020
accepted: 10 10 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 26 2 2021
Statut: epublish

Résumé

I

Identifiants

DOI: 10.3390/ijms21207674 PMID: 33081324 PMC: PMC7589297
pubmed: 33081324
pii: ijms21207674
doi: 10.3390/ijms21207674
pmc: PMC7589297
pii:
doi:

Substances chimiques

Iron Chelating Agents 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
Iron E1UOL152H7
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27
Deferasirox V8G4MOF2V9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Pathol. 2020 Jul;251(3):284-296
pubmed: 32304229
Oncogene. 2005 Dec 8;24(55):8093-104
pubmed: 16044147
Bioinformatics. 2005 May 1;21(9):2067-75
pubmed: 15657102
Cell Mol Life Sci. 2018 Mar;75(5):889-903
pubmed: 28975370
Blood Rev. 2018 Sep;32(5):368-377
pubmed: 29602612
J Cell Physiol. 2006 Nov;209(2):468-80
pubmed: 16883569
Database (Oxford). 2011 Jul 23;2011:bar030
pubmed: 21785142
Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a001131
pubmed: 20595397
Anticancer Res. 2011 May;31(5):1741-4
pubmed: 21617233
Cell Death Differ. 1999 Dec;6(12):1162-8
pubmed: 10637431
Nature. 1992 Mar 19;356(6366):215-21
pubmed: 1552940
J Clin Invest. 2010 Jun;120(6):2070-80
pubmed: 20484818
PLoS One. 2009 Nov 11;4(11):e7784
pubmed: 19907659
Cancer Sci. 2009 Jan;100(1):9-16
pubmed: 19018762
Oncotarget. 2016 Oct 4;7(40):65001-65011
pubmed: 27542250
Free Radic Biol Med. 2012 Aug 15;53(4):643-8
pubmed: 22705364
Cancer Sci. 2009 May;100(5):970-7
pubmed: 19298223
Am J Pathol. 2010 Feb;176(2):1006-17
pubmed: 20019189
Cell Rep. 2014 Apr 10;7(1):180-93
pubmed: 24685134
J Cell Mol Med. 2018 Feb;22(2):823-833
pubmed: 28994238
Haematologica. 2020 Mar;105(3):640-651
pubmed: 31278207
Onco Targets Ther. 2019 Apr 16;12:2903-2910
pubmed: 31289443
Biol Chem Hoppe Seyler. 1995 Oct;376(10):627-30
pubmed: 8590632
Oncotarget. 2015 Oct 6;6(30):29694-711
pubmed: 26335183
Biochemistry. 2012 Jul 24;51(29):5705-24
pubmed: 22703180
Neurodegener Dis. 2014;14(1):39-51
pubmed: 24192706
PLoS One. 2012;7(8):e43564
pubmed: 22952705
Biochim Biophys Acta. 2005 Jan 7;1706(1-2):1-11
pubmed: 15620362
Free Radic Biol Med. 2019 Mar;133:276-294
pubmed: 29572098
Sci Rep. 2020 Jun 8;10(1):9156
pubmed: 32514107
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486249
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Leuk Res. 2012 Aug;36(8):1067-70
pubmed: 22564985
FASEB J. 2020 Feb;34(2):2451-2464
pubmed: 31908078
Nature. 1989 Dec 7;342(6250):705-8
pubmed: 2531845
Cancers (Basel). 2011 Mar 03;3(1):994-1013
pubmed: 24212651
FEBS Lett. 1997 Dec 22;420(1):25-7
pubmed: 9450543
Br J Haematol. 2017 Oct;179(1):83-97
pubmed: 28677895
J Clin Med. 2020 Mar 16;9(3):
pubmed: 32188030
Blood. 2005 Nov 1;106(9):3191-9
pubmed: 16014567
J Alzheimers Dis. 2010;20 Suppl 2:S551-68
pubmed: 20463401
PLoS One. 2012;7(12):e51426
pubmed: 23251530
Haematologica. 2010 Aug;95(8):1308-16
pubmed: 20534700
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7
pubmed: 18424558
Oncoscience. 2015 Nov 11;2(10):880-91
pubmed: 26682280
Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1066-1077
pubmed: 27836629
Oncogene. 2015 Aug 13;34(33):4300-10
pubmed: 25417702
Curr Biol. 1997 Oct 1;7(10):747-57
pubmed: 9368757
Cancer Res. 1994 Mar 1;54(5):1169-74
pubmed: 8118801
Genes Dev. 2017 Jun 15;31(12):1243-1256
pubmed: 28747430
Ann Hematol. 2017 Jul;96(7):1085-1095
pubmed: 28421266
Cell Death Dis. 2011 May 26;2:e164
pubmed: 21614094
FASEB J. 2012 May;26(5):2175-86
pubmed: 22321727
Curr Top Med Chem. 2004;4(15):1623-35
pubmed: 15579100
Adv Hematol. 2010;2010:
pubmed: 20871852
Oncotarget. 2015 Aug 28;6(25):21479-92
pubmed: 26025930
Nucleic Acids Res. 2009 Jan;37(Database issue):D674-9
pubmed: 18832364
Biochim Biophys Acta. 2012 Oct;1817(10):1833-8
pubmed: 22409868
Eur J Haematol. 2015 Apr;94(4):318-21
pubmed: 25082234
Acta Histochem. 2017 Apr;119(3):315-326
pubmed: 28314612
Bioinformatics. 2007 Jul 15;23(14):1846-7
pubmed: 17496320
J Neurochem. 2018 Dec;147(6):816-830
pubmed: 30380148
Oncogene. 2019 Aug;38(35):6256-6269
pubmed: 31332290
Leuk Res. 2010 Jul;34(7):864-70
pubmed: 20129667
Haematologica. 2006 Dec;91(12):1588-90
pubmed: 17145593
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12248-52
pubmed: 7991614
J Natl Cancer Inst. 2008 Jul 16;100(14):996-1002
pubmed: 18612130
Int J Mol Sci. 2020 May 25;21(10):
pubmed: 32466216
Ann Hematol. 2017 Aug;96(8):1379-1388
pubmed: 28585071
J Pathol. 1999 Jan;187(1):112-26
pubmed: 10341712
Nature. 2002 Apr 4;416(6880):560-4
pubmed: 11932750
Oncotarget. 2016 Nov 8;7(45):74082-74096
pubmed: 27765915
Mol Cell. 2001 Mar;7(3):683-94
pubmed: 11463392
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Transfusion. 2010 Jan;50(1):190-9
pubmed: 19719471
Clin Cancer Res. 2011 Dec 15;17(24):7625-33
pubmed: 22052937
Front Neurol. 2018 May 30;9:384
pubmed: 29899726
Sci Data. 2017 Oct 10;4:170151
pubmed: 28994825
Cell. 2008 May 30;133(5):930-30.e1
pubmed: 18510935
Leuk Res. 2014 May;38(5):557-63
pubmed: 24661630
Carcinogenesis. 2003 Oct;24(10):1601-14
pubmed: 12869419
Mol Cell Biol. 2000 May;20(9):3224-33
pubmed: 10757806
Mol Cell Biol. 1999 May;19(5):3257-66
pubmed: 10207051
J Biol Chem. 2004 Feb 27;279(9):8076-83
pubmed: 14634023
Blood Rev. 2018 Jan;32(1):29-35
pubmed: 28847531
Nature. 1997 May 15;387(6630):296-9
pubmed: 9153395
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
Cold Spring Harb Perspect Biol. 2010 Sep;2(9):a004887
pubmed: 20484388
Oncogene. 1999 Jul 8;18(27):3923-9
pubmed: 10435614
Biochim Biophys Acta. 2009 May;1787(5):414-20
pubmed: 19007744
Nat Rev Cancer. 2002 Aug;2(8):594-604
pubmed: 12154352
Oncogene. 1999 Nov 1;18(45):6145-57
pubmed: 10557106
J Ethnopharmacol. 2015 Apr 2;163:192-202
pubmed: 25639816

Auteurs

Chiara Calabrese (C)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Cristina Panuzzo (C)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Serena Stanga (S)

Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10126 Turin, Italy.
ORCID: 0000-0003-1454-0713

Giacomo Andreani (G)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
ORCID: 0000-0003-4877-3929

Silvia Ravera (S)

Human Anatomy Section, Department of Experimental Medicine, University of Genoa, 16132 Genova, Italy.
ORCID: 0000-0002-0803-1042

Alessandro Maglione (A)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
ORCID: 0000-0001-7153-2248

Lucrezia Pironi (L)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Jessica Petiti (J)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
ORCID: 0000-0001-8640-2462

Muhammad Shahzad Shahzad Ali (MS)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Patrizia Scaravaglio (P)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Francesca Napoli (F)

Department of Oncology, University of Turin, 10043 Turin, Italy.

Carmen Fava (C)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Marco De De Gobbi (M)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Francesco Frassoni (F)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Giuseppe Saglio (G)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Enrico Bracco (E)

Department of Oncology, University of Turin, 10043 Turin, Italy.
ORCID: 0000-0003-3170-2817

Barbara Pergolizzi (B)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

Daniela Cilloni (D)

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
ORCID: 0000-0001-6346-4791

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Déférasirox › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Fer › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Agents séquestrants › Chélateurs › Agents chélateurs du fer › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Cellules › Structures cellulaires › Fractions subcellulaires › Mitochondries › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Stabilité protéique › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines proto-oncogènes c-mdm2 › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Deferasirox-Dependent Iron Chelation Enhances...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Deferasirox-Dependent Iron Chelation Enhances...